Sinovac Biotech, Ltd
SVA
SVA was delisted on the 22nd of February, 2019.
29 hedge funds and large institutions have $383M invested in Sinovac Biotech, Ltd in 2023 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
0% more funds holding
Funds holding: 29 → 29 (0)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
60% less capital invested
Capital invested by funds: $961M → $383M (-$578M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$15K |
| 2 |
YMRC
Yorktown Management & Research Company
Forest,
Virginia
|
+$2.25K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
|
-$39 |
SVA Hedge Fund Activity: Q3 2023 in Review
29 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Sinovac Biotech, Ltd (SVA) for Q3 2023, worth a combined $383M — down 60% from $961M a quarter earlier.
Fund positioning in SVA was balanced in Q3 2023: 0 funds opened new positions, 0 closed out, 2 added to existing stakes and 1 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $15K. The largest seller was Northwestern Mutual Wealth Management, cutting an estimated $39.
- 29 institutional investors held Sinovac Biotech, Ltd (SVA) as of Q3 2023, unchanged from Q2 2023.
- Funds reported $383M of Sinovac Biotech, Ltd stock for Q3 2023, down 60% quarter-over-quarter.
- 0 funds opened new Sinovac Biotech, Ltd positions in Q3 2023 and 0 closed out.
- The largest Sinovac Biotech, Ltd buyer in Q3 2023 was Morgan Stanley, an estimated $15K added.
- The largest Sinovac Biotech, Ltd seller in Q3 2023 was Northwestern Mutual Wealth Management, an estimated $39 sold.
Based on aggregated 13F filings for Q3 2023.